UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach

Drug metabolism and disposition, 2017-04, Vol.45 (4), p.409-417

2017

Volltextzugriff (PDF)

Functional Properties of a High Protein Beverage Stabilized with Oat‐β‐Glucan

Journal of food science, 2018-05, Vol.83 (5), p.1360-1365

2018

Volltextzugriff (PDF)

Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs

Journal of medicinal chemistry, 2020-10, Vol.63 (20), p.11831-11844

2020

Volltextzugriff (PDF)

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

Pharmaceutical research, 2012-10, Vol.29 (10), p.2860-2873

2012

Volltextzugriff (PDF)

Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

Clinical pharmacology and therapeutics, 2019-10, Vol.106 (4), p.792-802

2019

Volltextzugriff (PDF)

Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10–2474

ACS chemical biology, 2019-02, Vol.14 (2), p.192-197

2019

Volltextzugriff (PDF)

Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors

Pharmacotherapy, 2016-09, Vol.36 (9), p.986-993

2016

Volltextzugriff (PDF)

Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion

Drug metabolism and disposition, 2012-08, Vol.40 (8), p.1527-1537

2012

Volltextzugriff (PDF)

Targeting intestinal transporters for optimizing oral drug absorption

Current drug metabolism, 2010-11, Vol.11 (9), p.730-742

2010

Volltextzugriff (PDF)

Opportunities and Progress

Annual review of food science and technology, 2014-01, Vol.5 (1), p.23-37

Litchfield, John H

2014

Volltextzugriff (PDF)

Medicinal chemistry design principles for liver targeting through OATP transporters

Current topics in medicinal chemistry, 2013-04, Vol.13 (7), p.857-866

2013

Volltextzugriff (PDF)

Pharmacological inhibition of IRAK4 kinase activity does not prevent cachexia in mice with pancreatic cancer

JCSM rapid communications, 2023-07, Vol.6 (2), p.122-133

2023

Volltextzugriff (PDF)

Metabolism of PF-04958242: Substrate concentration-dependent impact of cytochrome P4503A4 inhibitors as an explanation for a lack of clinical drug–drug interaction at very low substrate doses

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S47-S47

2018

Volltextzugriff (PDF)

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates

EJNMMI research, 2022-03, Vol.12 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle

Bioorganic & medicinal chemistry letters, 2009-06, Vol.19 (12), p.3247-3252

2009

Volltextzugriff (PDF)

AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats

Archives of biochemistry and biophysics, 2003-04, Vol.412 (1), p.42-46

2003

Volltextzugriff (PDF)

Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature

Cardiovascular & hematological disorders drug targets, 2012-07, Vol.12 (1), p.21-27

2012

Volltextzugriff (PDF)

Chronic granulomatous disease, the McLeod phenotype and the contiguous gene deletion syndrome-a review

Clinical and molecular allergy CMA, 2011-11, Vol.9 (1), p.13-13, Article 13

2011

Volltextzugriff (PDF)

Novel Method to Predict In Vivo Liver-to-Plasma K puu for OATP Substrates Using Suspension Hepatocytes

Drug metabolism and disposition, 2017-05, Vol.45 (5), p.576-580

2017

Volltextzugriff (PDF)

A Physiologically Based in Silico Tool to Assess the Risk of Drug-Related Crystalluria

Journal of medicinal chemistry, 2020-06, Vol.63 (12), p.6489-6498

2020

Volltextzugriff (PDF)

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

Clinical pharmacology and therapeutics, 2022-09, Vol.112 (3), p.605-614

2022

Volltextzugriff (PDF)

Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease

Drug metabolism and disposition, 2022-09, Vol.50 (9), p.1312-1321

2022

Volltextzugriff (PDF)

Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver

The AAPS journal, 2020-01, Vol.22 (2), p.20, Article 20

2020

Volltextzugriff (PDF)

Friend or Foe, Pain from My Pain Pills? A Rare Case of Drug-Induced Acute Pancreatitis: 205

The American journal of gastroenterology, 2013-10, Vol.108, p.S64-S65

2013

Volltextzugriff (PDF)

Modeling Exposure to Understand and Predict Kidney Injury

Seminars in nephrology, 2019-03, Vol.39 (2), p.176-189

2019

Volltextzugriff (PDF)

1 – 25 von 259

Suche als RSS-Feed

Aktive Filter

ThemaLaws, Regulations And Rules

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(181)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(259)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach

Functional Properties of a High Protein Beverage Stabilized with Oat‐β‐Glucan

Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10–2474

Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors

Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion

Targeting intestinal transporters for optimizing oral drug absorption

Opportunities and Progress

Medicinal chemistry design principles for liver targeting through OATP transporters

Pharmacological inhibition of IRAK4 kinase activity does not prevent cachexia in mice with pancreatic cancer

Metabolism of PF-04958242: Substrate concentration-dependent impact of cytochrome P4503A4 inhibitors as an explanation for a lack of clinical drug–drug interaction at very low substrate doses

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates

Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle

AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats

Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature

Chronic granulomatous disease, the McLeod phenotype and the contiguous gene deletion syndrome-a review

Novel Method to Predict In Vivo Liver-to-Plasma K puu for OATP Substrates Using Suspension Hepatocytes

A Physiologically Based in Silico Tool to Assess the Risk of Drug-Related Crystalluria

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease

Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver

Friend or Foe, Pain from My Pain Pills? A Rare Case of Drug-Induced Acute Pancreatitis: 205

Modeling Exposure to Understand and Predict Kidney Injury

Aktive Filter

Suchergebnisse filtern